Will Cash Price Transparency Benefit Patients?: State Insurance Regulation Matters

David Hyman; Sunjay Letchuman; Ge Bai

doi:10.1001/jamahealthforum.2024.4322

Will Cash Price Transparency Benefit Patients?: State Insurance Regulation Matters

JAMA Health Forum. 2024 Dec 6;5(12):e244322. doi: 10.1001/jamahealthforum.2024.4322.

Authors

David Hyman¹, Sunjay Letchuman², Ge Bai^{3

4}

Affiliations

¹ Georgetown University Law Center, Washington, DC.
² Icahn School of Medicine at Mount Sinai, New York, New York.
³ Johns Hopkins Carey Business School, Washington, DC.
⁴ Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Washington, DC.

PMID: 39705043
DOI: 10.1001/jamahealthforum.2024.4322

No abstract available

Plain language summary

This Viewpoint discusses the ways in which cash price transparency might influence patients’ choice of clinician and how this would affect health care costs.